Topiramate Capsule, Extended Release
Product Images NDC 10370-365

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 10370-365). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Endo Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure.jpg (Topiramate Extended Release Capsules 1)

Chemical structure diagram of Topiramate, showing its molecular arrangement with multiple rings and functional groups including a sulfate moiety, as depicted in the image.*

FDA Label Image

Figure 1.jpg (Topiramate Extended Release Capsules 2)

A line graph comparing cumulative rates to first seizure for Topiramate at 50 mg/day and 400 mg/day over 500 days. The x-axis represents time in days, and the y-axis shows cumulative rates to first seizure. The graph includes data for 234 subjects at 50 mg/day and 236 subjects at 400 mg/day, with a significance value of p=0.0002.*

FDA Label Image

Figure 2: Reduction In 4-week Migraine Headache Frequency (studies 1 And 2 For Adults And Adolescents) (Topiramate Extended Release Capsules 3)

A bar graph comparing the change from baseline to double-blind phase in average monthly migraine period rate between placebo and topiramate at doses of 50 mg/day, 100 mg/day, and 200 mg/day across two studies. The graph displays data with error bars representing standard error (±SE), showing dose-dependent reductions in migraine rates for topiramate groups compared to placebo. Statistical significance is indicated for certain doses with p-values less than 0.010 and 0.001.*

FDA Label Image

Topiramate 25 mg (Topiramate Extended Release Capsules 4)

Label for Topiramate Extended-Release Capsules 25 mg, oral dosage form, containing 30 capsules. The label indicates these capsules are once daily, with an orange opaque cap and body. Distributed by Par Pharmaceutical and manufactured by Par Formulations Private Limited.*

FDA Label Image

Topiramate 50 mg (Topiramate Extended Release Capsules 5)

Label for Topiramate Extended-Release Capsules 50 mg by PAR Pharmaceutical. The label indicates 30 capsules per container, with instructions to swallow capsules whole. It includes storage information and a barcode, along with distributor details for Par Pharmaceutical and manufacturer info for Par Formulations Private Limited.*

FDA Label Image

Topiramate 100 mg (Topiramate Extended Release Capsules 6)

Topiramate Extended-Release Capsules 100 mg, 30 count bottle label showing once daily oral capsules. The label instructs to swallow capsules whole and intact, provides storage instructions at 20° to 25°C, and includes pharmacist dispensing instructions. Distributed by Par Pharmaceutical and manufactured by Par Formulations Private Limited, India. The capsules have an orange opaque cap and flesh opaque body.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.